---
layout: default
title: Vemurafenib
parent: 僅模型預測 (L5)
nav_order: 718
evidence_level: L5
indication_count: 10
---

# Vemurafenib
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

Using the evidence pack as provided (multi-candidate pack for DB08881), below is the report focused on the top-ranked prediction, with a supplementary table covering the other nine candidates for completeness.

---

# Vemurafenib: From Metastatic Melanoma (BRAF V600E) to HIV Infectious Disease

## One-Sentence Summary

> Vemurafenib is a selective BRAF V600E kinase inhibitor; the supporting literature in this evidence pack consistently describes its established use in **BRAF V600E-mutant metastatic melanoma**. The TxGNN model's top-ranked prediction is **HIV infectious disease**, but this is supported by **zero clinical trials and zero publications** — the model score is not corroborated by any external evidence in this pack.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not formally recorded in regulatory data (drug not registered in Australia); literature evidence in this pack repeatedly identifies vemurafenib as a treatment for **BRAF V600E-mutant metastatic melanoma** |
| Predicted New Indication | HIV infectious disease |
| TxGNN Prediction Score | 97.65% |
| Evidence Level | L5 (model prediction only, no supporting trials or literature) |
| Australia Market Status | Not marketed |
| Number of ARTG Entries | 0 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

Detailed mechanism-of-action data was not available in this evidence pack (flagged as a High-severity data gap, DG002). Based on the literature evidence that was collected, vemurafenib is consistently described as "a specific inhibitor of mutated BRAF kinase" and "a selective oral inhibitor of the BRAFV600 kinase," used to treat BRAF V600E-mutant melanoma by blocking downstream MAPK/ERK signalling.

For the top-ranked prediction, HIV infectious disease, the evidence pack's own rationale states there is **no known mechanistic link**: vemurafenib's target (BRAF V600E kinase) has no established interaction with HIV viral replication, reverse transcription, or host immune pathways relevant to viral control. The high TxGNN score most likely reflects an indirect connection through immune-related nodes in the knowledge graph, rather than genuine pharmacological plausibility. On the evidence available, this prediction should be treated as speculative and not mechanistically grounded.

---

## Clinical Trial Evidence

Currently no related clinical trials registered for HIV infectious disease.

---

## Literature Evidence

Currently no related literature available for HIV infectious disease.

---

## Other Predicted Indications (Lower Priority, Not Further Assessed)

This evidence pack contained 10 TxGNN-predicted indications for vemurafenib. None reached an evidence level above L4, and none received a recommendation other than Hold. For transparency, all are summarised below:

| Rank | Disease | TxGNN Score | Evidence Level | Recommendation | Note |
|------|---------|------|------|------|------|
| 1 | HIV infectious disease | 97.65% | L5 | Hold | No mechanistic link; no evidence |
| 2 | Neurodevelopmental disorder (ataxic gait, absent speech) | 96.73% | L5 | Hold | Rare paediatric genetic disorder; safety concerns re: BRAF inhibition in developing CNS |
| 3 | Feline acquired immunodeficiency syndrome | 96.56% | L5 | Hold | Animal (feline) disease, not a human indication |
| 4 | Simian immunodeficiency virus infection | 96.56% | L5 | Hold | Non-human primate model virus, not a human indication |
| 5 | Acute intermittent porphyria | 96.21% | L5 | Hold | No mechanistic link; CYP3A4 metabolism raises unassessed risk in porphyria |
| 6 | Collagenopathy | 95.32% | L5 | Hold | No mechanistic link |
| 7 | Paratenonitis | 95.25% | L5 | Hold | Vemurafenib is a known cause of arthralgia — opposite direction of effect |
| **8** | **Female breast carcinoma** | **95.15%** | **L4** | **Hold** | 1 withdrawn early-phase trial (0 enrolled); literature includes a **case report of vemurafenib-induced breast cancer progression** via paradoxical MAPK activation in BRAF-wildtype tumours — this is a **safety signal against use**, not supporting evidence |
| 9 | Calcific tendinitis | 95.13% | L5 | Hold | No mechanistic link; arthralgia is a known adverse effect, opposite direction |
| 10 | Lymphocytic hypereosinophilic syndrome | 94.996% | L5 | Hold | No mechanistic link |

**Clinically important note on Rank 8 (breast carcinoma):** this is the only candidate with clinical trial and literature evidence in the pack, but the evidence points toward **potential harm rather than benefit**. Vemurafenib has theoretical activity only in the small (<2%) subset of BRAF V600E-mutant breast cancers, while in BRAF-wildtype tumours it can paradoxically activate MAPK/ERK signalling and accelerate progression — the same mechanism responsible for vemurafenib-induced cutaneous squamous cell carcinoma. A published case report (PMID 26264150) directly documents disease progression in a breast cancer patient. This candidate should not be pursued without molecular confirmation of BRAF V600E status and specialist oncology input.

---

## Australia Market Information

Vemurafenib currently has **no ARTG entries** and is **not marketed** in Australia. No TGA-approved Product Information is available for this product in this jurisdiction.

---

## Cytotoxicity

Vemurafenib is a BRAF V600E-targeted oncology agent (literature in this pack repeatedly describes its use in metastatic melanoma), so this section applies.

| Item | Content |
|------|------|
| Cytotoxicity Classification | Targeted therapy (BRAF V600E kinase inhibitor) — not a conventional cytotoxic agent |
| Myelosuppression Risk | Not assessed in this evidence pack; please refer to the Product Information (PI) warnings and precautions |
| Emetogenicity Classification | Not assessed in this evidence pack; please refer to the Product Information (PI) warnings and precautions |
| Monitoring Items | Based on adverse events reported in the literature in this pack: skin examination for secondary cutaneous squamous cell carcinoma/keratoacanthoma, rash severity monitoring, ocular symptoms (uveitis reported), liver function (hepatic CYP3A4 metabolism noted in rationale) |
| Handling Protection | Oral formulation; standard institutional handling precautions for oral oncology agents recommended. No structured handling data available in this pack — refer to PI |

---

## Safety Considerations

As Vemurafenib is not currently registered in Australia, no TGA-approved Product Information is available. Key warnings, contraindications, and drug-interaction data were flagged as data gaps in this evidence pack (DG001, Blocking severity) and could not be assessed. **This is a blocking gap for any safety review (S1) of this candidate.**

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The top-ranked prediction (HIV infectious disease, 97.65% TxGNN score) has no supporting clinical trials or literature and no plausible mechanistic link (Evidence Level L5). The drug is not registered in Australia (0 ARTG entries), and PI/safety data are missing at Blocking severity (DG001). Among all 10 predicted indications reviewed, the only one with any clinical/literature evidence (female breast carcinoma) points toward a potential harm signal rather than therapeutic benefit.

**To proceed, the following is needed:**
- Resolve DG001 (TFDA/PI warnings and contraindications) — blocking for S1 safety review
- Resolve DG002 (confirmed mechanism of action) — needed for mechanistic plausibility assessment
- If any candidate is pursued further, prioritise indications with plausible BRAF V600E/MAPK pathway involvement over the current top-ranked (HIV) prediction
- If breast carcinoma is considered for future investigation, require BRAF V600E mutation confirmation and specialist oncology review given the documented paradoxical progression risk
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

